Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

InterMune stock plunges 80% as FDA rejects lung drug

By Hibah Yousuf, staff reporter


NEW YORK (CNNMoney.com) -- Shares of InterMune Inc. plunged nearly 80% after-hours Tuesday following the Food and Drug Administration's rejection of the biotech company's application for Esbriet, a drug designed to treat a fatal lung disease.

The company said the FDA has requested an additional clinical trial to support the effectiveness of Esbriet in patients suffering from idiopathic pulmonary fibrosis, which hinders the body's ability to process oxygen due to inflammation and scarring in the lungs.

"We will meet with the FDA as soon as possible to understand their points of view and to determine the most appropriate path forward to expeditiously make Esbriet available to the approximately 100,000 patients with IPF and their families who suffer from this terrible disease and for whom no FDA-approved medicines exist," InterMune (ITMN) chairman and chief executive Dan Welch said in a prepared statement.

Welch said he was "disappointed" by the outcome, since the FDA's advisory committee recommended the approval of the drug by a 9-3 margin in March.  To top of page

Index Last Change % Change
Dow 18,094.83 -166.62 -0.91%
Nasdaq 5,257.49 -48.26 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
Treasuries 1.59 -0.03 -1.61%
Data as of 1:38am ET
Company Price Change % Change
Bank of America Corp... 15.09 -0.43 -2.77%
Procter & Gamble Co 87.85 0.09 0.10%
Wells Fargo & Co 44.88 -0.86 -1.88%
Apple Inc 112.88 0.17 0.15%
Pfizer Inc 33.64 -0.62 -1.81%
Data as of Sep 26
Sponsors

Sections

Wells Fargo shares closed below $45 on Monday for the first time since early 2014, the latest sign that the fake account scandal is causing real financial damage. More

A new analysis estimates that under Trump's tax plan, roughly 20% of households with children and more than half of single parents would pay more in taxes than they do today. More

Two years before the government pulled the plug on its funding, the for-profit school faced lawsuits over how it misled students about the quality of its programs and job placement rates. More